Literature DB >> 15792997

Interactions between delta and mu opioid agonists in assays of schedule-controlled responding, thermal nociception, drug self-administration, and drug versus food choice in rhesus monkeys: studies with SNC80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and heroin.

Glenn W Stevenson1, John E Folk, Kenner C Rice, S Stevens Negus.   

Abstract

Interactions between delta and mu opioid agonists in rhesus monkeys vary as a function of the behavioral endpoint. The present study compared interactions between the delta agonist SNC80 [(+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and the mu agonist heroin in assays of schedule-controlled responding, thermal nociception, and drug self-administration. Both SNC80 (ED50 = 0.43 mg/kg) and heroin (ED50 = 0.088 mg/kg) produced a dose-dependent and complete suppression of response rates in the assay of schedule-controlled responding. Heroin also produced thermal antinociception (ED(5 degrees C) = 0.18 mg/kg) and maintained drug self-administration under both a fixed ratio schedule [dose-effect curve peak at 0.0032 mg/kg/injection (inj)] and under a food versus heroin concurrent-choice schedule (ED50 = 0.013 mg/kg/inj), whereas SNC80 did not produce thermal antinociception or maintain self-administration. Fixed ratio mixtures of SNC80 and heroin (1.6:1, 4.7:1, and 14:1 SNC80/heroin) produced additive effects in the assay of schedule-controlled responding and superadditive effects in the assay of thermal nociception. Also, SNC80 did not enhance the reinforcing effects of heroin, indicating that mixtures of SNC80 and heroin produced additive or infra-additive reinforcing effects. These results provide additional evidence to suggest that delta/mu interactions depend on the experimental endpoint and further suggest that delta agonists may selectively enhance the antinociceptive effects of mu agonists while either not affecting or decreasing the sedative and reinforcing effects of mu agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15792997     DOI: 10.1124/jpet.104.082685

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  30 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Influence of δ-opioid receptors in the behavioral effects of nicotine.

Authors:  Fernando Berrendero; Ainhoa Plaza-Zabala; Lola Galeote; África Flores; S Andreea Bura; Brigitte L Kieffer; Rafael Maldonado
Journal:  Neuropsychopharmacology       Date:  2012-06-06       Impact factor: 7.853

3.  Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics.

Authors:  Matthew L Banks; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2010-08-03       Impact factor: 3.533

4.  Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.

Authors:  Omar S Mabrouk; Riccardo Viaro; Mattia Volta; Ada Ledonne; Nicola Mercuri; Michele Morari
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

Review 5.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

6.  Synaptic mechanism for functional synergism between delta- and mu-opioid receptors.

Authors:  Zhi Zhang; Zhizhong Z Pan
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

7.  Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2.

Authors:  Ana Vicente-Sanchez; Isaac J Dripps; Alycia F Tipton; Heba Akbari; Areeb Akbari; Emily M Jutkiewicz; Amynah A Pradhan
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

8.  δ-Opioid receptor agonists inhibit migraine-related hyperalgesia, aversive state and cortical spreading depression in mice.

Authors:  Amynah A Pradhan; Monique L Smith; Jekaterina Zyuzin; Andrew Charles
Journal:  Br J Pharmacol       Date:  2014-05       Impact factor: 8.739

Review 9.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

10.  Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects.

Authors:  Bradford D Fischer; Sara J Ward; Fredrick E Henry; Linda A Dykstra
Journal:  Neuropharmacology       Date:  2009-08-21       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.